## J Nicholas Cochran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7110283/publications.pdf

Version: 2024-02-01

759233 996975 23 666 12 15 citations h-index g-index papers 29 29 29 1805 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Medicine, 2017, 9, 43.	8.2	188
2	The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Research Bulletin, 2014, 103, 18-28.	3.0	89
3	Aberrant Inclusion of a Poison Exon Causes Dravet Syndrome and Related SCN1A-Associated Genetic Epilepsies. American Journal of Human Genetics, 2018, 103, 1022-1029.	6.2	76
4	Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. American Journal of Human Genetics, 2020, 106, 632-645.	6.2	50
5	De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 2018, 137, 375-388.	3.8	46
6	The Alzheimer's disease risk factor CD2AP maintains blood–brain barrier integrity. Human Molecular Genetics, 2015, 24, 6667-6674.	2.9	38
7	Alzheimer's disease risk gene BIN1 induces Tau-dependent network hyperexcitability. ELife, 2020, 9, .	6.0	35
8	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. Acta Neuropathologica, 2019, 137, 71-88.	7.7	29
9	Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles. Journal of Physical Education and Sports Management, 2019, 5, a003491.	1.2	25
10	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiology of Aging, 2017, 49, 216.e7-216.e13.	3.1	22
11	AlphaScreen HTS and Live-Cell Bioluminescence Resonance Energy Transfer (BRET) Assays for Identification of Tau–Fyn SH3 Interaction Inhibitors for Alzheimer Disease. Journal of Biomolecular Screening, 2014, 19, 1338-1349.	2.6	21
12	A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid- $\hat{l}^2$ toxicity. Neurobiology of Disease, 2020, 134, 104668.	4.4	19
13	Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy. PLoS Genetics, 2021, 17, e1009195.	3.5	18
14	PEA15 loss of function and defective cerebral development in the domestic cat. PLoS Genetics, 2020, 16, e1008671.	3.5	4
15	Response to Holstege etÂal American Journal of Human Genetics, 2020, 107, 577-578.	6.2	1
16	Title is missing!. , 2021, 17, e1009195.		0
17	Title is missing!. , 2021, 17, e1009195.		O
18	Title is missing!. , 2021, 17, e1009195.		0

#	Article	IF	CITATIONS
19	Title is missing!. , 2021, 17, e1009195.		O
20	PEA15 loss of function and defective cerebral development in the domestic cat., 2020, 16, e1008671.		O
21	PEA15 loss of function and defective cerebral development in the domestic cat., 2020, 16, e1008671.		O
22	PEA15 loss of function and defective cerebral development in the domestic cat., 2020, 16, e1008671.		0
23	PEA15 loss of function and defective cerebral development in the domestic cat., 2020, 16, e1008671.		O